These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 32699149)

  • 1. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19.
    Cauchois R; Koubi M; Delarbre D; Manet C; Carvelli J; Blasco VB; Jean R; Fouche L; Bornet C; Pauly V; Mazodier K; Pestre V; Jarrot PA; Dinarello CA; Kaplanski G
    Proc Natl Acad Sci U S A; 2020 Aug; 117(32):18951-18953. PubMed ID: 32699149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.
    Bozzi G; Mangioni D; Minoia F; Aliberti S; Grasselli G; Barbetta L; Castelli V; Palomba E; Alagna L; Lombardi A; Ungaro R; Agostoni C; Baldini M; Blasi F; Cesari M; Costantino G; Fracanzani AL; Montano N; Monzani V; Pesenti A; Peyvandi F; Sottocorno M; Muscatello A; Filocamo G; Gori A; Bandera A
    J Allergy Clin Immunol; 2021 Feb; 147(2):561-566.e4. PubMed ID: 33220354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
    Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK
    Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine storm and use of anakinra in a patient with COVID-19.
    Nemchand P; Tahir H; Mediwake R; Lee J
    BMJ Case Rep; 2020 Sep; 13(9):. PubMed ID: 32933914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report.
    Franzetti M; Pozzetti U; Carugati M; Pandolfo A; Molteni C; Faccioli P; Castaldo G; Longoni E; Ormas V; Iemoli E; Piconi S
    Int J Infect Dis; 2020 Aug; 97():215-218. PubMed ID: 32422376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis.
    Dimopoulos G; de Mast Q; Markou N; Theodorakopoulou M; Komnos A; Mouktaroudi M; Netea MG; Spyridopoulos T; Verheggen RJ; Hoogerwerf J; Lachana A; van de Veerdonk FL; Giamarellos-Bourboulis EJ
    Cell Host Microbe; 2020 Jul; 28(1):117-123.e1. PubMed ID: 32411313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open label trial of anakinra to prevent respiratory failure in COVID-19.
    Kyriazopoulou E; Panagopoulos P; Metallidis S; Dalekos GN; Poulakou G; Gatselis N; Karakike E; Saridaki M; Loli G; Stefos A; Prasianaki D; Georgiadou S; Tsachouridou O; Petrakis V; Tsiakos K; Kosmidou M; Lygoura V; Dareioti M; Milionis H; Papanikolaou IC; Akinosoglou K; Myrodia DM; Gravvani A; Stamou A; Gkavogianni T; Katrini K; Marantos T; Trontzas IP; Syrigos K; Chatzis L; Chatzis S; Vechlidis N; Avgoustou C; Chalvatzis S; Kyprianou M; van der Meer JW; Eugen-Olsen J; Netea MG; Giamarellos-Bourboulis EJ
    Elife; 2021 Mar; 10():. PubMed ID: 33682678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series.
    Navarro-Millán I; Sattui SE; Lakhanpal A; Zisa D; Siegel CH; Crow MK
    Arthritis Rheumatol; 2020 Dec; 72(12):1990-1997. PubMed ID: 32602262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of anakinra in severe COVID-19: A case report.
    Filocamo G; Mangioni D; Tagliabue P; Aliberti S; Costantino G; Minoia F; Bandera A
    Int J Infect Dis; 2020 Jul; 96():607-609. PubMed ID: 32437934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment.
    González-García A; García-Sánchez I; Lopes V; Moreno-Arrones OM; Tortosa-Cabañas M; Elías-Sáenz I; Hernández-Rodríguez J
    Rheumatology (Oxford); 2020 Aug; 59(8):2171-2173. PubMed ID: 32568376
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia.
    Pontali E; Volpi S; Signori A; Antonucci G; Castellaneta M; Buzzi D; Montale A; Bustaffa M; Angelelli A; Caorsi R; Giambruno E; Bobbio N; Feasi M; Gueli I; Tricerri F; Calautti F; Castagnola E; Moscatelli A; Rollandi GA; Ravelli A; Cassola G; Sormani MP; Gattorno M
    J Allergy Clin Immunol; 2021 Apr; 147(4):1217-1225. PubMed ID: 33556464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking IL-1 to prevent respiratory failure in COVID-19.
    van de Veerdonk FL; Netea MG
    Crit Care; 2020 Jul; 24(1):445. PubMed ID: 32682440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease.
    Pontali E; Volpi S; Antonucci G; Castellaneta M; Buzzi D; Tricerri F; Angelelli A; Caorsi R; Feasi M; Calautti F; Castagnola E; Rollandi GA; Ravelli A; Cassola G; Gattorno M
    J Allergy Clin Immunol; 2020 Jul; 146(1):213-215. PubMed ID: 32437739
    [No Abstract]   [Full Text] [Related]  

  • 14. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra).
    Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G; Toniato E
    J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1623-1627. PubMed ID: 32744052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care.
    Quartuccio L; Sonaglia A; McGonagle D; Fabris M; Peghin M; Pecori D; De Monte A; Bove T; Curcio F; Bassi F; De Vita S; Tascini C
    J Clin Virol; 2020 Aug; 129():104444. PubMed ID: 32570043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empiric Therapeutic Anticoagulation and Mortality in Critically Ill Patients With Respiratory Failure From SARS-CoV-2: A Retrospective Cohort Study.
    Ferguson J; Volk S; Vondracek T; Flanigan J; Chernaik A
    J Clin Pharmacol; 2020 Nov; 60(11):1411-1415. PubMed ID: 32885463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality.
    Imazio M; Brucato A; Lazaros G; Andreis A; Scarsi M; Klein A; De Ferrari GM; Adler Y
    J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):625-629. PubMed ID: 32658005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement.
    Day JW; Fox TA; Halsey R; Carpenter B; Kottaridis PD
    Br J Haematol; 2020 Jul; 190(2):e80-e83. PubMed ID: 32438450
    [No Abstract]   [Full Text] [Related]  

  • 19. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.
    van de Veerdonk FL; Netea MG; van Deuren M; van der Meer JW; de Mast Q; Brüggemann RJ; van der Hoeven H
    Elife; 2020 Apr; 9():. PubMed ID: 32338605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS.
    Cascella M; Mauro I; De Blasio E; Crispo A; Del Gaudio A; Bimonte S; Cuomo A; Ascierto PA
    Medicina (Kaunas); 2020 Jul; 56(8):. PubMed ID: 32727107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.